Mediapharma S.r.l.

Consiglio Nazionale Delle Ricerche

Fusion Pharmaceuticals Inc.

Janus Pharma S.r.l.

Stefano Iacobelli

Gianluca Sala

Annalisa Di Risio

Emily Capone

Raffaella Muraro

Enza Piccolo

Nicola Tinari

Sara Traini

Vincenzo Fogliano

Mauro Piantelli

The present disclosure relates to the generation of an antibody that specifically recognizes and binds Endosialin, a cell surface antigen characteristic of tumor pericytes and cells of tumor stroma. The antibody has the ability to become internalized in Endosialin expressing cells and to block the activation of MAPK in PDGF stimulated human pericytes. The antibody is able to block angiogenesis induced by LGALS3BP, a known Endosialin interactor and to inhibit tumor growth alone and in combination with 1959, a humanized antibody against LGALS3BP in human osteosarcoma xenograft. Furthermore, upon conjugation of the humanized version of the anti-Endosialin antibody with a duocarmycin derivative, the resulting ADC displays potent and antigen dependent in vitro tumor cell cytotoxicity and effective antitumor efficacy in vivo. The disclosure is also related to nucleotides encoding the antibodies of the disclosure and cell expressing the antibodies.

Endosialin-binding antibody

The present invention relates to an antibody, particularly a monoclonal antibody, which binds to the ErbB3 receptor, compositions comprising such an antibody as well as methods using such an antibody.

ErbB3 binding antibody

The present invention relates to the use of anti-90K monoclonal antibodies for prevention and treatment of tumors and metastases thereof. In particular, the invention relates to the use of anti-90K monoclonal antibodies able to inhibit the adhesive processes of tumor cells and angiogenesis in tumors such as breast cancer, ovarian cancer, lung cancer, gastrointestinal cancer, melanoma, lymphoma and other tumors overexpressing 90K.

Use of anti-90K monoclonal antibodies for the prevention and treatment of tumors and metastases thereof

A method for in vitro immunoassaying an antigen from biological fluids or tissues. The antigen is present in individuals infected with the AIDS virus. The antigen is of cytoplasmic origin and is recognized by an SP-2 monoclonal antibody produced by a hybridoma cell line deposited at the Collection Nationale de Cultures de Microorganisms, Accession, No. I-1083. The method comprises the steps of taking a sample of biological fluid or tissue from a person; contacting the biological fluids or tissues with the antibody; removing an amount of the antibody not binding with the antigen; and determining the amount of the antibody bound with the antigen utilizing at least one revealing system selected from the group consisting of enzyme, radioisotope, and chemiluminescent labels.

Use of the SP-2 monoclonal antibody for the clinical diagnostics and for

Growing community of inventors

Rome, Italy

Stefano Iacobelli